The Relationship between Glycemic Control and Plasma Vascular Endothelial Growth Factor and Endothelin-1 Concentration in Diabetic Patients

Hiroaki Kakizawa, Mitsuyasu Itoh, Yasutoshi Itoh, Shigeo Imamura, Yoko Ishiwata, Takashi Matsumoto, Keiko Yamamoto, Taiya Kato, Yasunaga Ono, Mutsuko Nagata, Nobuki Hayakawa, Atsushi Suzuki, Yoshie Goto, Naohisa Oda

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Understanding the causes of diabetic vascular complications has become an increasingly important issue because of the rapidly rising prevalence of diabetes. Recently discovered vasoconstrictors and angiogenesis regulators, such as endothelin (ET) and vascular endothelial growth factor (VEGF), have been intensely studied for possible pathogenic roles in diabetic vascular complications. The present study was undertaken to clarify the effect of glycemic control on serum VEGF and plasma ET-1 concentrations in diabetic patients, and to identify other factors that may cause fluctuations of these substances. Plasma VEGF and ET-1 concentrations of 45 hospitalized diabetic patients and 54 control subjects were measured by enzyme immunoassay (EIA) and radioimmunoassay (RIA), respectively. Plasma VEGF was elevated in poorly controlled diabetic patients compared with healthy subjects and plasma VEGF concentrations declined after hospitalized treatment with either insulin or oral hypoglycemic agents in combination with diet. There was a significant correlation between plasma VEGF concentration and both fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c). Plasma ET-1 in poorly controlled diabetic patients was higher than in healthy controls, but improved glycemic control did not affect plasma ET-1 concentrations. Thus, poor glycemic control causes increased levels of plasma VEGF, which may result in hypertension and vascular complications in diabetes. Short-term treatment resulting in good glycemic control can improve levels of VEGF and may provide beneficial effects on diabetic vascular complications.

Original languageEnglish
Pages (from-to)550-555
Number of pages6
JournalMetabolism: Clinical and Experimental
Volume53
Issue number5
DOIs
Publication statusPublished - 01-01-2004

Fingerprint

Endothelin-1
Vascular Endothelial Growth Factor A
Diabetic Angiopathies
Endothelins
Vasoconstrictor Agents
Diabetes Complications
Immunoenzyme Techniques
Hypoglycemic Agents
Radioimmunoassay
Blood Vessels
Fasting
Healthy Volunteers
Hemoglobins
Insulin
Diet
Hypertension
Glucose
Therapeutics
Serum

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Kakizawa, Hiroaki ; Itoh, Mitsuyasu ; Itoh, Yasutoshi ; Imamura, Shigeo ; Ishiwata, Yoko ; Matsumoto, Takashi ; Yamamoto, Keiko ; Kato, Taiya ; Ono, Yasunaga ; Nagata, Mutsuko ; Hayakawa, Nobuki ; Suzuki, Atsushi ; Goto, Yoshie ; Oda, Naohisa. / The Relationship between Glycemic Control and Plasma Vascular Endothelial Growth Factor and Endothelin-1 Concentration in Diabetic Patients. In: Metabolism: Clinical and Experimental. 2004 ; Vol. 53, No. 5. pp. 550-555.
@article{fe3f74a204ed46e4b04ddbfb48648d08,
title = "The Relationship between Glycemic Control and Plasma Vascular Endothelial Growth Factor and Endothelin-1 Concentration in Diabetic Patients",
abstract = "Understanding the causes of diabetic vascular complications has become an increasingly important issue because of the rapidly rising prevalence of diabetes. Recently discovered vasoconstrictors and angiogenesis regulators, such as endothelin (ET) and vascular endothelial growth factor (VEGF), have been intensely studied for possible pathogenic roles in diabetic vascular complications. The present study was undertaken to clarify the effect of glycemic control on serum VEGF and plasma ET-1 concentrations in diabetic patients, and to identify other factors that may cause fluctuations of these substances. Plasma VEGF and ET-1 concentrations of 45 hospitalized diabetic patients and 54 control subjects were measured by enzyme immunoassay (EIA) and radioimmunoassay (RIA), respectively. Plasma VEGF was elevated in poorly controlled diabetic patients compared with healthy subjects and plasma VEGF concentrations declined after hospitalized treatment with either insulin or oral hypoglycemic agents in combination with diet. There was a significant correlation between plasma VEGF concentration and both fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c). Plasma ET-1 in poorly controlled diabetic patients was higher than in healthy controls, but improved glycemic control did not affect plasma ET-1 concentrations. Thus, poor glycemic control causes increased levels of plasma VEGF, which may result in hypertension and vascular complications in diabetes. Short-term treatment resulting in good glycemic control can improve levels of VEGF and may provide beneficial effects on diabetic vascular complications.",
author = "Hiroaki Kakizawa and Mitsuyasu Itoh and Yasutoshi Itoh and Shigeo Imamura and Yoko Ishiwata and Takashi Matsumoto and Keiko Yamamoto and Taiya Kato and Yasunaga Ono and Mutsuko Nagata and Nobuki Hayakawa and Atsushi Suzuki and Yoshie Goto and Naohisa Oda",
year = "2004",
month = "1",
day = "1",
doi = "10.1016/j.metabol.2003.12.002",
language = "English",
volume = "53",
pages = "550--555",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "5",

}

Kakizawa, H, Itoh, M, Itoh, Y, Imamura, S, Ishiwata, Y, Matsumoto, T, Yamamoto, K, Kato, T, Ono, Y, Nagata, M, Hayakawa, N, Suzuki, A, Goto, Y & Oda, N 2004, 'The Relationship between Glycemic Control and Plasma Vascular Endothelial Growth Factor and Endothelin-1 Concentration in Diabetic Patients', Metabolism: Clinical and Experimental, vol. 53, no. 5, pp. 550-555. https://doi.org/10.1016/j.metabol.2003.12.002

The Relationship between Glycemic Control and Plasma Vascular Endothelial Growth Factor and Endothelin-1 Concentration in Diabetic Patients. / Kakizawa, Hiroaki; Itoh, Mitsuyasu; Itoh, Yasutoshi; Imamura, Shigeo; Ishiwata, Yoko; Matsumoto, Takashi; Yamamoto, Keiko; Kato, Taiya; Ono, Yasunaga; Nagata, Mutsuko; Hayakawa, Nobuki; Suzuki, Atsushi; Goto, Yoshie; Oda, Naohisa.

In: Metabolism: Clinical and Experimental, Vol. 53, No. 5, 01.01.2004, p. 550-555.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Relationship between Glycemic Control and Plasma Vascular Endothelial Growth Factor and Endothelin-1 Concentration in Diabetic Patients

AU - Kakizawa, Hiroaki

AU - Itoh, Mitsuyasu

AU - Itoh, Yasutoshi

AU - Imamura, Shigeo

AU - Ishiwata, Yoko

AU - Matsumoto, Takashi

AU - Yamamoto, Keiko

AU - Kato, Taiya

AU - Ono, Yasunaga

AU - Nagata, Mutsuko

AU - Hayakawa, Nobuki

AU - Suzuki, Atsushi

AU - Goto, Yoshie

AU - Oda, Naohisa

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Understanding the causes of diabetic vascular complications has become an increasingly important issue because of the rapidly rising prevalence of diabetes. Recently discovered vasoconstrictors and angiogenesis regulators, such as endothelin (ET) and vascular endothelial growth factor (VEGF), have been intensely studied for possible pathogenic roles in diabetic vascular complications. The present study was undertaken to clarify the effect of glycemic control on serum VEGF and plasma ET-1 concentrations in diabetic patients, and to identify other factors that may cause fluctuations of these substances. Plasma VEGF and ET-1 concentrations of 45 hospitalized diabetic patients and 54 control subjects were measured by enzyme immunoassay (EIA) and radioimmunoassay (RIA), respectively. Plasma VEGF was elevated in poorly controlled diabetic patients compared with healthy subjects and plasma VEGF concentrations declined after hospitalized treatment with either insulin or oral hypoglycemic agents in combination with diet. There was a significant correlation between plasma VEGF concentration and both fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c). Plasma ET-1 in poorly controlled diabetic patients was higher than in healthy controls, but improved glycemic control did not affect plasma ET-1 concentrations. Thus, poor glycemic control causes increased levels of plasma VEGF, which may result in hypertension and vascular complications in diabetes. Short-term treatment resulting in good glycemic control can improve levels of VEGF and may provide beneficial effects on diabetic vascular complications.

AB - Understanding the causes of diabetic vascular complications has become an increasingly important issue because of the rapidly rising prevalence of diabetes. Recently discovered vasoconstrictors and angiogenesis regulators, such as endothelin (ET) and vascular endothelial growth factor (VEGF), have been intensely studied for possible pathogenic roles in diabetic vascular complications. The present study was undertaken to clarify the effect of glycemic control on serum VEGF and plasma ET-1 concentrations in diabetic patients, and to identify other factors that may cause fluctuations of these substances. Plasma VEGF and ET-1 concentrations of 45 hospitalized diabetic patients and 54 control subjects were measured by enzyme immunoassay (EIA) and radioimmunoassay (RIA), respectively. Plasma VEGF was elevated in poorly controlled diabetic patients compared with healthy subjects and plasma VEGF concentrations declined after hospitalized treatment with either insulin or oral hypoglycemic agents in combination with diet. There was a significant correlation between plasma VEGF concentration and both fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c). Plasma ET-1 in poorly controlled diabetic patients was higher than in healthy controls, but improved glycemic control did not affect plasma ET-1 concentrations. Thus, poor glycemic control causes increased levels of plasma VEGF, which may result in hypertension and vascular complications in diabetes. Short-term treatment resulting in good glycemic control can improve levels of VEGF and may provide beneficial effects on diabetic vascular complications.

UR - http://www.scopus.com/inward/record.url?scp=2342519443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342519443&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2003.12.002

DO - 10.1016/j.metabol.2003.12.002

M3 - Article

VL - 53

SP - 550

EP - 555

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 5

ER -